Chief Physician and Professor of the Department of Respiratory and Critical Care Medicine , specializing in rare respiratory diseases and pulmonary vascular diseases
Affiliated HospitalPeking Union Medical College Hospital, Chinese Academy of Medical Sciences
→
Research areas: Clinical and basic research on rare respiratory diseases such as lymphangioleiomyomatosis (LAM) and pulmonary alveolar proteinosis (PAP), and pulmonary hypertension.
Cutting-edge technology: Pioneered the clinical use of rapamycin for LAM treatment in China, establishing the largest follow-up population of LAM patients in the country. Introduced novel blood testing methods for PAP and LAM, potentially achieving a diagnostic accuracy rate of over 90%. Undertook a National 973 Program project, focusing on the mechanism of the mTOR signaling pathway in lung injury and fibrosis. A key base for clinical trials of pulmonary hypertension in China, conducting multiple domestic and international multicenter drug clinical trials.
Specializes in treating: lymphangioleiomyomatosis, pulmonary alveolar proteinosis, sarcoidosis, pulmonary hypertension, bronchiectasis, and pleural diseases (chylothorax, pleural effusion).
Academic Highlights and Core Values: Studied at the University of Melbourne, Australia from 1995 to 1997; worked at the Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) in the United States from 2002 to 2005. Founder of LAM China website and head of the "LAM/TSC Rare Disease Charity Project".